Effect of Loratadine Combined with Pidotimod Assisted with Ribavirin in the Treatment of Recurrent Respiratory Tract Infection
Objective:To investigate the efficacy of loratadine combined with pidotimod and ribavirin in the treatment of recurrent respiratory infections(RRI).Methods:A total of 120 patients with RRI admitted to our hospital from July 2021 to September 2023 were selected and randomly divided into experimental group(60 patients,ribavirin,loratadine combined with pidotimod)and control group(60 patients,ribavirin).The pharyngeal normal time,lung rale disappearance time,cough relief time,inflammatory factors[C-reactive protein(CRP),granulocyte macrophage colony stimulating factor(GM-CSF)],immune function[Immunoglobulin A(IgA),Immunoglobulin G(IgG),Immunoglobulin M(IgM)and natural killer cell(NK cell)]were observed in the two groups.Results:The pharyngeal normal time,lung rale disappearance time and cough relief time in the experimental group were shorter than those in the control group(P<0.05).After treatment,the levels of CRP and GM-CSF in the experimental group were lower than those in the control group,and the levels of IgA,IgG,IgM and NK cells were higher than those in the control group(P<0.05).Conclusion:Ribavirin,loratadine combined with pidotimod can help reduce the inflammatory response in patients with RRI,improve their immune function,and promote their rapid recovery.
NETL
NSTL
万方数据
